Scolaris Content Display Scolaris Content Display

Study flow diagram.
Figures and Tables -
Figure 1

Study flow diagram.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 The empty rows relate to abstract‐only publications ‐ risk of bias could not be assessed
Figures and Tables -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
The empty rows relate to abstract‐only publications ‐ risk of bias could not be assessed

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 1 Number starting RRT.
Figures and Tables -
Analysis 1.1

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 1 Number starting RRT.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 2 GFR.
Figures and Tables -
Analysis 1.2

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 2 GFR.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 3 Reduction in GFR.
Figures and Tables -
Analysis 1.3

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 3 Reduction in GFR.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 4 Serum creatinine.
Figures and Tables -
Analysis 1.4

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 4 Serum creatinine.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 5 Increase in serum creatinine.
Figures and Tables -
Analysis 1.5

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 5 Increase in serum creatinine.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 6 Haemoglobin.
Figures and Tables -
Analysis 1.6

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 6 Haemoglobin.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 7 Haematocrit.
Figures and Tables -
Analysis 1.7

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 7 Haematocrit.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 8 Number of patients transfused.
Figures and Tables -
Analysis 1.8

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 8 Number of patients transfused.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 9 Quality of life measures.
Figures and Tables -
Analysis 1.9

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 9 Quality of life measures.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 10 Change in exercise capacity.
Figures and Tables -
Analysis 1.10

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 10 Change in exercise capacity.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 11 Systolic blood pressure.
Figures and Tables -
Analysis 1.11

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 11 Systolic blood pressure.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 12 Diastolic blood pressure.
Figures and Tables -
Analysis 1.12

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 12 Diastolic blood pressure.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 13 Number with an increase or introduction of antihypertensive treatment.
Figures and Tables -
Analysis 1.13

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 13 Number with an increase or introduction of antihypertensive treatment.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 14 Number discontinued due to adverse events.
Figures and Tables -
Analysis 1.14

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 14 Number discontinued due to adverse events.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 15 Seizures.
Figures and Tables -
Analysis 1.15

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 15 Seizures.

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 16 Mortality.
Figures and Tables -
Analysis 1.16

Comparison 1 rHuEPO versus placebo or no rHuEPO, Outcome 16 Mortality.

Comparison 1. rHuEPO versus placebo or no rHuEPO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number starting RRT Show forest plot

6

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Starting RRT during the study period

5

207

Risk Ratio (M‐H, Random, 95% CI)

0.70 [0.43, 1.14]

1.2 Starting RRT in the follow‐up to the study

1

8

Risk Ratio (M‐H, Random, 95% CI)

3.0 [0.50, 17.95]

2 GFR Show forest plot

7

283

Mean Difference (IV, Random, 95% CI)

‐2.11 [‐3.08, ‐1.15]

3 Reduction in GFR Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

4 Serum creatinine Show forest plot

8

327

Mean Difference (IV, Random, 95% CI)

27.86 [‐32.04, 87.76]

5 Increase in serum creatinine Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

6 Haemoglobin Show forest plot

4

237

Mean Difference (IV, Random, 95% CI)

‐1.90 [‐2.34, ‐1.47]

7 Haematocrit Show forest plot

7

145

Mean Difference (IV, Random, 95% CI)

‐9.85 [‐11.34, ‐8.35]

8 Number of patients transfused Show forest plot

3

111

Risk Ratio (M‐H, Random, 95% CI)

0.32 [0.12, 0.83]

9 Quality of life measures Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

10 Change in exercise capacity Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

11 Systolic blood pressure Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

12 Diastolic blood pressure Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

13 Number with an increase or introduction of antihypertensive treatment Show forest plot

4

232

Risk Ratio (M‐H, Random, 95% CI)

1.26 [0.76, 2.11]

14 Number discontinued due to adverse events Show forest plot

4

223

Risk Ratio (M‐H, Random, 95% CI)

0.86 [0.28, 2.59]

15 Seizures Show forest plot

3

140

Risk Ratio (M‐H, Random, 95% CI)

0.22 [0.02, 1.94]

16 Mortality Show forest plot

4

182

Risk Ratio (M‐H, Random, 95% CI)

0.60 [0.13, 2.88]

Figures and Tables -
Comparison 1. rHuEPO versus placebo or no rHuEPO